Teligent's Post-Sale Drug Recall Puts Its Ch. 11 Plan In Doubt
The Chapter 11 plan for the generic-drug maker once known as Teligent Inc. was thrown into doubt Friday after a bankruptcy court ruled that the company owes a refund for drugs it sold after bankruptcy and then later recalled as part of an asset sale.
Source: law360.com